STOCK TITAN

PTC Therapeutics (PTCT) officer sells 52,003 shares under 10b5-1 plan

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

PTC Therapeutics, Inc. reported that Chief Technical Operations Officer Neil Gregory Almstead sold a total of 52,003 shares of common stock in open‑market transactions on 2026-04-01 at prices around $69 per share.

After these sales, he directly holds 60,137 shares of PTC Therapeutics common stock and indirectly holds 2,737 shares through his spouse. The filing notes that the transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 11, 2025.

Positive

  • None.

Negative

  • None.
Insider Almstead Neil Gregory
Role CHIEF TECHNICAL OPS OFFICER
Sold 52,003 shs ($3.59M)
Type Security Shares Price Value
Sale Common Stock 39,393 $68.89 $2.71M
Sale Common Stock 12,530 $69.50 $871K
Sale Common Stock 80 $70.30 $6K
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 72,747 shares (Direct); Common Stock — 2,737 shares (Indirect, By Spouse)
Footnotes (1)
  1. This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $68.26 to $69.26 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $69.26 to $70.13 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Total shares sold 52,003 shares Open-market sales on 2026-04-01
Sale price (block 1) $68.89 per share Weighted average price for 39,393-share sale
Sale price (block 2) $69.50 per share Weighted average price for 12,530-share sale
Sale price (block 3) $70.30 per share Price for 80-share sale
Direct holdings after sales 60,137 shares Common stock directly owned post-transaction
Indirect holdings by spouse 2,737 shares Common stock held indirectly through spouse
Rule 10b5-1 plan adoption date November 11, 2025 Plan governing reported sales
Rule 10b5-1 plan regulatory
"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
open-market sale financial
"transaction_action: "open-market sale" with transaction code "S""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
weighted average price financial
"This price represents the weighted average price of sale transactions that were executed in multiple trades"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
indirect ownership financial
"ownership_type: "indirect" and nature_of_ownership: "By Spouse""
Form 4 regulatory
"INSIDER FILING DATA (Form 4)"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Almstead Neil Gregory

(Last)(First)(Middle)
C/O PTC THERAPEUTICS, INC.
500 WARREN CORPORATE CENTER DRIVE

(Street)
WARREN NEW JERSEY 07059

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
PTC THERAPEUTICS, INC. [ PTCT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
CHIEF TECHNICAL OPS OFFICER
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock04/01/2026S(1)39,393D$68.89(2)72,747D
Common Stock04/01/2026S(1)12,530D$69.5(3)60,217D
Common Stock04/01/2026S(1)80D$70.360,137D
Common Stock2,737IBy Spouse
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025.
2. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $68.26 to $69.26 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
3. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $69.26 to $70.13 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
/s/ Avraham S. Adler, Attorney-in-Fact04/03/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did PTC Therapeutics (PTCT) disclose for Neil Gregory Almstead?

PTC Therapeutics disclosed that Chief Technical Operations Officer Neil Gregory Almstead sold 52,003 shares of common stock in open‑market transactions on 2026-04-01. These trades were reported on a Form 4 insider filing and reflect routine reporting of executive share activity.

At what prices did Neil Gregory Almstead sell PTC Therapeutics (PTCT) shares?

Neil Gregory Almstead sold PTC Therapeutics shares at weighted average prices of $68.89, $69.50, and $70.30 per share. The filing notes these averages reflect multiple trades within price ranges around each figure, and detailed trade breakdowns are available upon request.

How many PTC Therapeutics (PTCT) shares does Neil Gregory Almstead hold after the reported sales?

Following the reported sales, Neil Gregory Almstead directly owns 60,137 PTC Therapeutics common shares. The filing also shows an additional 2,737 shares held indirectly through his spouse, providing a view of both his direct and related holdings after the transactions.

Were Neil Gregory Almstead’s PTC Therapeutics (PTCT) share sales made under a Rule 10b5-1 plan?

Yes. The filing states the transactions were effected under a written Rule 10b5-1 trading plan adopted on November 11, 2025. Such plans pre-schedule trades, helping separate routine portfolio management from discretionary timing decisions by company insiders.

How many PTC Therapeutics (PTCT) shares did Neil Gregory Almstead sell in total on 2026-04-01?

On 2026-04-01, Neil Gregory Almstead sold a total of 52,003 PTC Therapeutics common shares. This total comes from three separate open‑market sale entries reported on the Form 4, each at different weighted average prices in a narrow trading range.